Study design: Methodological.
Objective: Turkish validity and reliability study of Scoliosis Research Society-30 (SRS-30) questionnaire.
Summary of background data: SRS-30 is the most current questionnaire of SRS, which is widely used in the evaluation of the treatment of idiopathic scoliosis patients. There is no validity and reliability study for the Turkish language.
Methods: All translation and cross-cultural adaptation stages of the SRS-30 English version to Turkish were implemented. SRS-30 Turkish and Short Form-36 (SF-36) questionnaires were administered to 96 adolescent idiopathic scoliosis patients simultaneously. Two weeks later, the SRS-30-Turkish version was applied again. Internal validity was examined using the Rasch model, and external construct validity (convergent validity) was evaluated with the Spearman rho correlation test. Person Separation Index (PSI) was used for reliability. The internal consistency was analyzed with Cronbach alpha. For test re-test reliability, Intraclass Correlation Coefficient (ICC) between the two measurements was calculated.
Results: As a result of the Rasch analysis, it was observed that the Turkish version of SRS-30 has a multi-dimensional structure and the disordered threshold problem was observed in some items. Overall fit is provided for each of the 4 sub-dimensions of SRS-30 Turkish. There was no difference in the functioning of the items in terms of gender and age groups. The lowest PSI value was obtained with 0.539 in the satisfaction of the treatment sub-dimension. Cronbach alpha values were over 0.70 for all domains. The ICC value was found in Satisfaction with management dimension (0.463) and above 0.60 in other dimensions.
Conclusion: It was concluded that the SRS-30 Turkish questionnaire was valid and reliable in evaluating the treatment of adolescent idiopathic scoliosis patients. Considering the studies related to SRS scales in the literature, especially those applied Rasch analysis, it is seen that the reply categories of the items should be reviewed.Level of Evidence: 2.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.